An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
News Medical on MSN1d
Off-the-Shelf Immunotherapy Approach Shows Promise for B-Cell LymphomaA new type of off-the-shelf cell-based immunotherapy shows promise for B-cell lymphomas, and could make make future cellular ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...
The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...
While the trial was not designed to evaluate efficacy, Ghobadi and colleagues said that responses were observed across B-cell lymphoma histologies among those treated with the combination ...
Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...
In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback